Navigation Links
STALLERGENES : Further Profit Growth Acceleration of R&D Expenditure
Date:3/12/2008


PARIS, March 12 /PRNewswire-FirstCall/ --

- Further Profit Growth

- Sales up 16% - Profit Before R&D up 19%

- Net Profit (Group Share) up 12%

- Acceleration of R&D Expenditure The Board of Directors, meeting on 11 March 2008 under the chairmanship of Albert Saporta, approved the 2007 consolidated financial statements:

(EUR millions) 2007 As a % 2006 As a % 07/06

of sales of sales % change

Sales 147.1 100.0 126.6 100.0 16

Cost of sales (32.9) (22.3) (29.5) (23.3) 11

Gross profit 114.2 77.7 97.1 76.7 18

General, (65.1) (44.3) (55.9) (44.2) 17

administrative and

sales costs

Profit before R&D 49.1 33.4 41.2 32.5 19

Net R&D expenditure (23.8) (16.2) (18.0) (14.2) 32

Operating profit 25.3 17.2 23.2 18.3 9

(EBIT)

Net profit (Group 16.3 11.1 14.6 11.5 12

share)

Diluted earnings per EUR 1.22 EUR 1.11 10

share

Proposed dividend EUR 0.40 EUR 0.35 14

Net financial debt 10.4 (0.35) 12.0 (0.44) (14)

(x EBITDA)

Accelerated growth in 2007

Growth accelerated in all markets in 2007. The 16% sales increase reflects the vigour of sublingual route, which grew 21%, and its growing awareness among patients. Significant growth in the number of new patients confirmed growing interest in desensitisation for the treatment of allergic diseases.

This excellent sales level generated a 19% increase in profit before R&D, to EUR 49.1 million, and a 9% increase in operating profit (EBIT) to EUR 25.3 million. Net profit (Group share) was EUR 16.3 million, up 12% from the 2
'/>"/>

SOURCE Stallergenes
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
2. STALLERGENES and Protein eXpert Enter Into a Partnership for Producing Mites Recombinant Allergens
3. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
4. Stallergenes : 3rd Quarter Sales Up 17%: 9- Month Cumulative Sales Up 17%
5. STALLERGENES : Strong Business Growth: +17% and Earnings Per Share up 30%
6. MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio
7. CleveMed Receives $1.5 Million in NIH Funding to Further Develop a Portable System for Monitoring Parkinsons Disease Motor Symptoms
8. SAFC Hitech(TM) Plans Further Expansion Into Asia
9. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
10. Agencourt Genomic Services is Key Collaborator in New Research That Further Defines Landscape of Breast and Colon Cancers
11. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 Appistry, Inc. , a ... the power of genomics to next-generation medicine, announced today ... Challenge . , Two Appistry staff will be ... Center for Genome Resources, and Mr. Neil Miller, director ... Kansas City. Rounding out the panel are Appistry’s Dr. ...
(Date:7/28/2014)... COLLEGE STATION, Texas , July 28, 2014 /PRNewswire/ ... will be a 177-key, 4-star boutique hotel in the heart ... , Texas.  Photo - http://photos.prnewswire.com/prnh/20140725/130455 ... the first hotel within ATLAS , The ... mixture of standard rooms and suites, a sleek restaurant and bar, ...
(Date:7/25/2014)... "Ischemic Stroke and Cerebral Stroke ... on the Ischemic Stroke and Cerebral Stroke clinical ... data relating to the clinical trials on Ischemic ... Ischemic Stroke Research Report 2014 at: http://www.marketresearchreports.biz/analysis/213207 ... trial numbers and their recruitment status as per ...
(Date:7/25/2014)... -- Research and Markets  has announced the ... report to their offering. ... Metabonomics is the scientific study of chemical processes ... technique that is being widely used in biology, ... molecules that are present in blood, urine, and ...
Breaking Biology Technology:Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 3Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 4Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2
... with live study setup and launch..., WAYLAND, ... in bio-pharmaceutical clinical trials software, announces the,launch of ... studies. Trident,s unique parameter driven + custom pluggable ... to deliver a new era,of needed scalability, productivity, ...
... March 20 NexGen,Biofuels Ltd. (OTC:NXGNF) announced today ... shares have been approved for quotation on the,OTC-Bulletin ... a development stage company that is currently seeking ... blending assets in,the United States., For More ...
... Therapies Will Not Match, the Current Gold-Standard ... According to a New Report ... Decision Resources, one of the,world,s leading research and advisory ... drug Zactima from AstraZeneca,will earn 4.7 percent patient share ...
Cached Biology Technology:Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 2Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 3AstraZeneca's Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016 2
(Date:7/28/2014)... A study of juvenile rat brain cells suggests that ... the connections between brain cells are temporary. , The ... PLOS ONE , was conducted by biologists at ... Medical College in New York in response to concerns, ... decade, that exposing children to general anesthetics may increase ...
(Date:7/28/2014)... areas of the Earth that are high priorities for ... is particularly vulnerable, as it has the lowest fraction ... any continent in ,refugia, areas of biological diversity ... relatively constant during times of great environmental change. The ... Scandinavia and Scotland. , The biggest refugia are ...
(Date:7/28/2014)... tool that can help advance the genetic engineering ... bioenergy, has been developed by researchers with the ... (JBEI), a multi-institutional partnership led by Lawrence Berkeley ... developed an assay that enables scientists to identify ... critical components in the biosynthesis of plant cell ...
Breaking Biology News(10 mins):Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3Study finds Europe's habitat and wildlife is vulnerable to climate change 2How sweet it is 2How sweet it is 3
... clinical research is being done, warns a senior doctor ... is failing patients and clinicians by neglecting this vital ... information that doctors need to diagnose and treat patients ... field of neurology alone, many examples exist where a ...
... and Geoff Garnett (of Imperial College London) suggests that ... controlled through antiretroviral drugs alone, even if universal access ... the open-access international medical journal PLoS Medicine, without additional ... about safe sex, access to drugs is likely to ...
... causes mice to develop the metabolic syndrome, researchers at ... at OHSU, the University of Texas Medical Branch and ... lack the gene encoding the DNA repair enzyme NEIL1 ... twice the weight of their normal counterparts. The mice, ...
Cached Biology News:Access to antiretrovirals unlikely to reduce HIV infection rates 2Removing DNA repair gene causes metabolic syndrome 2Removing DNA repair gene causes metabolic syndrome 3
... Systems provide fast and reliable automation ... and drug development laboratories. Staccato Custom ... specifications, providing solutions that are tailored ... Custom Systems are controlled with either ...
... Not treated (or medium binding) polystyrene ... binds biomolecules through passive interactions,• Is ... large molecules, such as antibodies, that ... interact with the surface,• Binding capacity ...
... tabs • Reusable, press-to-seal gasket and ... assembled and disassembled for hybridizing and imaging ... thickness with up to a 13 mm ... slide. Minimize specimen handling, eliminate evaporation and ...
...
Biology Products: